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Abstract. The interest of science in compounds that have antioxidant, 
antitumoral and cardio protective properties and can be founded in 
food has risen in nowadays. The case of resveratrol, a stilbene founded 
in wine, originated from grape as response of the wine against the dam-
ages, is the biggest case of studies. Resveratrol took all this attention 
after the term of French Paradox that describe the low incidence of 
French population, in cardiovascular disease as they are known as a 
regular wine consumer. The evaluation of bioavailability and toxicity of 
resveratrol in organism has been conducted with both methods, in vitro 
and in vivo. A number of studies have given evidences about the path-
ways how resveratrol is metabolized, the mechanism of action and its 
pharmacokinetic properties. But even now that is clear how resveratrol 
metabolism works there are a lot of questions, but the question to take 
in consideration is: which is the best way to intake these compounds to 
produce a pharmacological effect? The key for a pharmacological effect 
is the bioavailability of non-metabolized resveratrol. Higher the quanti-
ty of non-metabolized resveratrol, higher is the pharmacological effect. 
Oral intakes from wine or supplements are the only ways of resveratrol 
delivery. Coupling the resveratrol with detonation nanodiamonds 
(DNDs) raises the bioavailability of resveratrol and its pharmacological 
effect. 
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Introduction. A carrier system able to use the full range of resveratrol 
(henceforth named RSV) properties is very important. Such a system can 
consist in immobilizing RSV with detonation nanodiamonds (refer to as 
DNDs). In 1963 a physicist from Ukraine noticed that soot from the explo-
sion of an explosive called Composition B, contained a carbon-based 
material that later was called detonation nanodiamond. His invaluable 
observation started the early discovery of detonation nanodiamond 
(DND) [1]. Resveratrol, which belongs to stilbenes, is targeted for long-
term treatments.Administration of RSV by oral routes is the favored one, 
but it is supposed that administering RSV through another drug delivery 
system via injection could be a potential therapeutic tool [2] to commute 
the step taken as limiting RSV’s bioavailability: intestinal metabolism. By 
using Composition B as a raw material and refining the crude products, 
an industrial production of DND is achieved. This route is known from 
1990 mainly in China and Russia. Of course, transformation of war explo-
sives into artificial nanodiamond is certainly the most attractive chemical 
conversion we have ever heard. The discovery of DND was kept secret 
under Soviet military regime, but gradually became known to the rest of 
the world after 1990s. DND has come into commercial market since the 
early 1990s as visible grey powder and has been listed in chemical cata-
logues under various trade names(Tab. 1) [3]. One of the concerns of RSV 
is its low solubility in water and the trend to be bound to plasma proteins 
to reach its target [4]. Confronted with the problem of low oral bioavaila-
bility there exist a range of options available. One of the options is to use 
the compound as an injectable agent [5]. To the best of our knowledge 
there exist no reports in the literature, focused on the particular coupling 
of DND with RSV. The aim of our study is to propose a delivery system for 
RSV based on chemical and physical approaches in order to rise the effi-
ciency of RSV treatments. 
 
Synthesis and purification of DND. DND known as “ultra dispersed dia-
mond,” is synthesized on a large scale by the detonation of carbon explo-
sives with a CxHyNoOz composition. An overall negative oxygen balance is 
required for the explosive mixture in the detonation chamber to impede 
the combustion of the carbon into its gaseous forms. Mostly a mixture of 
trinitrotoluene and hexogen in  various ratios is utilized, which provides 
the driving force of the reaction (Fig. 1). A shock wave produced by the 
detonator compresses and heats the composition mixture, leading to its 
explosion [6]. During this exothermic process is released an immense 
amount of energy, which brings the temperature in the detonation cham-
ber to 3000°C–4000°C and the pressure to 20–30 GPa. This is an ideal 
route for disposing old munitions, such as Composition B, although other 
explosives may be used, too. The detonation happens in a well-closed in 
the presence of an inert gas and a coolant. The product represents dia-
mond particles with dimension 4–5 nm in diameter, but there are pre-
sent different carbon allotropes and other impurities. The soot contains 
up to 75 weight % of diamond and the carbon yield is 4–10% of the 
weight of the explosive, depending on the reaction conditions. Moreover, 
to the diamond phase, the detonation soot contains both sp3 carbon (25–
85 weight %) and impurities (metals and oxides, 1–8 weight%) and it 
must be purified. The impurities represents a potential problem for puri-
fication process since they are attached to the outer surface of DND ag-
gregates, and for that they must be removed and extensively purified 
since one of the possible application might be in biomedical studies.[7] 
[8]. Depending on the materials and matrices present during their pro-
duction, the technology of chemical separation and purification of DND 
can be divided into three stages, namely: a) dissolution of the metallic 
component, b) dissolution of non-nanodiamond (sp2) forms of carbon 
(NDC) and c) the removal of contaminants. Each method of oxidation is 
based on the fact that NDC has a higher reactivity than diamond. There-
fore, detonation DNDs can contain different materials like oxides and 
carbides, including those of iron, chromium, silicon, calcium, copper, 
potassium, titanium, and sulfur, together with carbon soot [6]. Acidic 
solutions like mixtures of sulfuric and nitric acid are used to remove me-
tallic impurities form the surface [9]. A hydrofluoric acid and nitric acid 
combination has also been used to eliminate metallic contaminants from 
the particles [10]. Other oxidation mixtures for removal of sp2-bonded 
carbon structures can be sodium peroxide, chromium trioxide and sulfu-
ric acid mixture, or a nitric acid and hydrogen peroxide mixture [9]. If  
oxidation is carried out in air, higher temperatures which reach to 400°C–
430°C are required to obtain the oxidation of sp2-bonded carbon species 
[11]. Ozone is very efficient in removal of sp2-hybridized carbon species. 
The ozone-air treatment known as “gas phase treatment” is a friendly, 
efficient and capable method for increasing the diamond content from 
~25 wt% (detonation soot) to >95 wt%, as the purification of DNDs is 
achieved without using the corrosive liquid oxidizers [12]. 
 
Structure and properties of DND particles. Tetrahedral symmetry, which 
comes from sp3 hybridization  of carbon atoms,  in DND gives rise to a 
very strong structure. Merit in that has also the σ bonds neighboring 
carbon atoms. The inertness comes from the lack of free electrons in the 
structure of diamond. Nevertheless, the structure of surface of this mate-
rial is different from the bulk because of relaxation at the surface and 
also the need for bond termination. It includes univalent species such as 
OH or H. Based on particle sizes, Shenderova and McGuire classified 
DNDs into nanocrystalline particles (≥150nm), ultrananocrystalline parti-
cles (2 to 10 nm), and diamondoids (1 to 2 nm). Ultrananocrystalline 
diamond particles bear a special potential for biomedical applications and 
interest is shown in DNDs with a primary particle size of 4 to 5 nm [13]. 
To construct a model of DND structure, it must take into account the 
presence of various surface functional groups, sp2 carbon, and the shape 
of the particle. Its core is surrounded by a shell with irregular carbon 
structure, where carbon atoms occur in different hybridization states, 
(mainly sp2); also, there is a layer of surface functional groups which can 
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be identified by a complex of spectral and analytical methods (IR and 
Raman spectroscopy, solid-phase 13C NMR, electronic spectroscopy, ele-
mental analysis, etc.[14]. The structure organization of well-purified 
DNDs can be presented in Fig. 2. TEM analyses have shown that DND 
particles are organized in a structure  made of a sp3 carbon core, which 
may be coated by a graphitic shell, where there might be present func-
tional groups [15]. The model with polyhedral is shown in Fig. 3. Superior 
structure of diamond is delivered in DND structure. Some of these prop-
erties include biocompatibility, fluorescence, high thermal conductivity 
and chemical inertness. Sp3 core may be stabilized by the addition of 
organic groups or be transformed through chemical routes into sp2 car-
bon. So, the stability of carbon particles depends, even on the surface 
construction. [8].  High SSA, chemical inertness, and hydrophobicity make 
DNDs very important in using for  medical and sensor applications (Tab. 
2) [16b]. Application to biological and medical fields require a surface 
functionalization in order to improve the solubility in normal pH and to 
help binding to biological targets. Due to recent developments, methods 
for covalent functionalization of carbon nanomaterials are becoming an 
area of growing interest for industrial and biomedical applications (Fig. 4) 
[15].  
 
Applications of DND in drug delivery. In order to design a good drug 
delivery system, various properties are needed. We can mention here 
carrying therapeutics, dispersibility in water, and biocompatibilty. The 
potential for targeted therapy, possibly in combination with imaging, is 
even better. Nanodiamonds meet almost all of these requirements [15]. 
The electrostatic potential on the surface is an important factor in deter-
mining the preferred binding sites of biomolecules. The surface electro-
static potential is responsible for the agglomeration process of prepared 
nanodiamonds, due to coherent interfacial coulombic interactions. This 
happens because DNDs show an anisotropic distribution of surface elec-
trostatic potential between the facets, with (100) surface facets exhib-
iting a strong positive electrostatic potential while the (111) facets exhib-
it a negative electrostatic potential (depending upon the degree of sur-
face graphitisation)[16b]. This leads to an appropriate orientation be-
tween particles, interactions and self-assembly through them (Fig. 3). 
One reason why it is important to have a complete understanding of the 
surface chemistry of DNDs particles is that, depending upon the groups 
present, surfaces provide a unique platform for chemical modifications 
and ultimately for bioconjugation. Different models are proposed to 
show the binding modes between DNDs and other molecules (Fig. 5) 
[15]. Larger organic molecules and biomolecules can be attached on the 
surface of nanodiamond. But the binding mode depends strongly on the 
surface termination of the underlying material. For example, the surfaces 
of nanodiamond have been successfully carboxylated (one of the earliest 
modifications of the DND surface), which provides a high affinity for pro-
teins, and can be conjugated with biomolecules (Fig. 5). In addition, for a 
high surface loading, it is essential to achieve the homogeneity of sur-
face. In order to have a uniform reactivity reactions with hydrogen, chlo-
rine ect. are applied. These reactions can be used to further modified the 
surfaces of DNDs with hydroxyl, amine, and carbon fluoride groups[15]. 
Even why they are desirable for many other reasons, hydrogen terminat-
ed surfaces are much less likely to adsorb biomolecules, due to a lack of 
polar interaction in hydrogen bonding [17][18]. This is not the case for all 
nanodiamond surfaces. Oxidised surface become prone to polar interac-
tions [19][20]. In this case polarity gives rise to  non-covalent interaction 
between biomolecules and diamond surfaces [17][18]. It was demon-
strated that DND is a universal adsorbent, which stimulated rapid devel-
opment of studies in this line, primarily of those concerning sorption of 
complex organic molecules, biomonomers and biopolymers. In particular, 
DND was shown to efficiently adsorb carbohydrates, amino acids, humic 
compounds, nucleic acids and proteins. The application of DNDs as ad-
sorbents has been developed, and specific prospects were opened just in 
the use of DNDs for medical and biological targets. Relevant studies have 
shown that DND tuned out to be very effective for the isolation of vari-
ous biomolecules from complex biological systems. Detonation nanodia-
monds have found application for fractionation of similar molecules, 
purification of proteins, and isolation of DNA. The sorption capacity (q) of 
DND is related to the particle size (R) according to Eq. 1: 
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Method Source Year Obtained Product Size 
HPHTa Graphite and Fe General Electric (1955) Single crystalline particles 50μm 
Shock Explosive, Cu and Graphite De Carli-Jamieson (1961) Polycrystalline particles 50μm 
Detonation TNT and RDX in water Danilenko-Volkov-Elin (1963) Single crystalline nanoparticles 4nm 
CVD CH4 and H2
b Eversole (1950) Polycrystalline Films Thickness can be as large as mm 
Table 1. Different ways of Nanodiamonds production. aHydrostatic high-pressure high-temperature. bA number of variations exist.  
Property Characteristics Application 
Biological 
  
Biocompatibility; Easily bind bio-active substance (DNA, pro-
teins); Low level of toxicity. 
  
  
Organ and cell studies; Target molecules, labels, hormones, 
inhibitors antigens and drugs. 
  
Chemical 
Numerous oxygen containing groups on surface; High chemical 
purity; Chemically resistant to degradation/corrosion, pH sta-
bility; Possible sp2 carbon shells; Functionalization of surface; 
Large number of unpaired electrons on the surface. 
  
Adsorption of hydrophobic molecules; Implants, coatings, 
substrates for cell  growth; Hydrophilic, water dispersible sus-
pension for further coupling to bio-entities  into other matri-
ces; Coupling of drugs and biomolecules (polymers, metal 
composite material); X-ray protective coatings and surfaces, 
detection devices. 
Electrochemical Electrochemical plating with metals; Redox behavior. 
Chem/biosensors, potential production of ROS; Improve dura-
bility, life of medical instruments/implants 
Mechanical 
Fine abrasive; High strength and hardness. 
  
Composite additive, possible cell lysis, delivery to tissue and 
cells; Homogenization of composites/cosmetics, skin polishing. 
Optical 
High refractive index , optical transparency; Photolumines-
cence, non-photobleaching, non-blinking, originates from N-
vacancy defects; Raman spectral signal. 
Scattering optical label for live cells, possible UV sunscreen; 
Fluorescent probe and imaging tool for bioimaging; Non- de-
structive detection with living cell. 
Structural 
Large specific surface area (300-400 m2/g); Particles primary 
monocrystalline (4-5nm); Different forms (particulate, coating, 
substrate); Low porosity/permeability of films; High specific 
gravity (3.5 g/cm2); Variable size and narrow size fractions 
High affinity capacity for binding proteins, 
enzymes, enterosorbents, purification; Component of small 
pore membrane for extended time storage; Dense structure 
for solid phase support; Diverse application based on size ( UV 
protection). 
Technical 
Inexpensive, mass production; Can be synthesized in industrial 
scale. 
Availability of various quality/purity samples. 
Thermal Durable in very high/low temperatures. 
Sterilization , composite manufacturing , liquid nitrogen stor-
age. 
Table 2. Properties of DNDs. 
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q = (0.39±0.05) – (0.0026±0.0004)R; where n = 7, r = 
0.97 [Eq. 1] [14]. 
 
It is admitted that sorption capacity of DND toward other molecules is 
also determined by their nature and largely by the properties of this 
molecule, for example proteins [14]. In particular, the use of nanodia-
monds as human anti-cancer agents is already showing promising results 
[21]. DNDs attached to chemotherapeutics have been shown higher effi-
cacy, better elution, and provide a slower release of the drugs that may 
be tunable, meanwhile retaining the conformation and activity of the 
attached molecules during all the process. In summary, because of its 
high surface free energy, DNDs do not exist as single particles, but form 
clusters in the range of nanometers in a low free energy. This happens 
even when they are dispersed in a solution by applying ultrasonication. 
The high hardness and nanoscale pores, formed between particles, leads 
to an assembly of drugs and other molecules on the surface of DNDs by 
non-covalent interaction. At the end, different distributions are obtained  
in DNDs clusters [22]. Before nanoparticles can be used for any bio-
medical application, the toxicity of the material must be quantified and 
minimized, but numerous in vitro and in vivo animal studies have shown 
that these particles are biocompatible and have no or little toxic side 
effect on biological systems. Different results obtained by Schrand et al. 
have shown that DNDs have non-toxic activity to a variety of different 
cells [23]. It is obvious because we are dealing with diamond structure, 
where there is no chemical reactivity. Anyway, various studies have 
demonstrated that the toxicity of DNDs can vary depending upon their 
surface chemistry, purity, dimensions of particles, type of cell line, and 
the composition of the treatment medium [15]. Stilbenes. Stilbenes are 
small (MW 210-270 g/mol) compounds found in nature and present in 
some plants like Celastraceae, Cyperaceae, Fabaceae, Moraceae and 
Vitaceae, aromatherapy products, and dietary supplements. They are 
phytoalexins, which means that they are induced by infections and me-
chanical stress. Stilbenes exist in the Z (trans) and E (cis) forms. In the 
literature has been shown that both exhibit different pharmacological 
activities there are reports that the Z form shows more potent activity 
compared to the E form across various anti-cancer and anti-oxidant as-
says. One such study demonstrated trans-resveratrol to be ten times 
more efficient to stimulate apoptosis in the HL60 leukemia cell line com-
pared to cis-resveratrol [24]. This can be confirmed by research related to 
cyclooxygenase I (COX-I) activity [25]. There are several stilbenes that 
have been recognized and classified (Tab. 3) [26]. They are similar with 
flavonoids, isoflavonoids and lignans, all derived via the phenylpropanoid 
pathway (Fig. 6). Resveratrol. Resverastrol, which is present in wine and 
several plants, has been shown to have a number of properties that could 
be useful to the human health. This compound has been known to scien-
tists for several decades, but it gained interest only in 1990s, when it was 
reported for the first time to be present in red wine [27], leading to ideas 
that resveratrol might contribute to the ‘‘French paradox’’ [28]. As we 
mentioned resveratrol is present in red wine and consumption of red 
wine protects against cardiovascular disease [29], so it is hypothesized 
that it could be a protective agent against cardiovascular disease, even 
though wine contains several other polyphenolic compounds (e.g. quer-
cetin, catechin), tannins and alcohol that might participate in cardiovas-
cular protection. It exhibits direct antioxidant activity, an anti-
inflammatory effect, and inhibits the effects of vascular cell adhesion 
molecule expression. Resveratrol also bears antitumor activity [30], par-
ticularly against colorectal cancer cells, and might be a good drug against 
Alzheimer’s disease [31]. Recently, resveratrol has been shown to mimic 
caloric restriction [32], and extend the lifespan of a number of species 
from yeasts [33] to mice [32]. Resveratrol is commercially available as a 
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Figure 1. Synthesis Steps of DNDs Synthesis. I)Explosion in which explo-
sives with a negative oxygen balance (for example a mix of 60 wt% TNT 
(C6H2(NO2)3CH3) and 40 wt% hexogen (C3H6N6O6) are detonated in a 
closed metallic chamber in an atmosphere of N2, CO2 and liquid or ice. 
After detonation, diamond-containing soot is collected from the bottom 
and the walls of the chamber. II) The formation of carbon nanoclusters; 
(III) The coagulation into liquid nanodroplets; (IV) The crystallization and 
agglomeration of nanodiamonds. 
Figure 2. Schematic representation of DND structure. 
Figure 3. Schematic model of DND structure like a truncated octahedron. 
The (100) faces are hatched, (111) faces are not hatched. On the (111) 
faces are attached different functional groups, such as the hydroxyl, 
carboxyl, epoxy, anhydride, methyl, methilene, methine as most likely 
ones to become attached to DND. Most of them are attached during 
purification process [16a]. 
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dietary supplement  and represents a potential medical compound. 
Chemically, resveratrol is available as a  powder solid with molecular 
formula C14H12O3, molecular weight of 228.25 g
.mol−1 and a melting point 
between 253 and 255°C [34]. It is soluble in ethanol at ~50 mg.ml−1 (~200 
mM) and in DMSO at ~16 mg.ml −1 (~70 mM) [35]. However, its hydro-
solubility of ~3 mg.100ml−1 (~0.13 mM) makes it “practically insoluble” in 
water according to the European Pharmacopeia definition, and its log P is 
3.1 [36]. In Fig. 7 is presented 3D structures of two forms of RSV. The 
biological activity of the trans-isomer is greater than the cis-isomer [37]. 
It comes due to its nonplanar conformation [38]. 
 
Challenges in the delivery of phenolic bioactives. Actually RSV is orally 
taken and it seems to be the preferred route, except for special applica-
tion. However, it is supposed that administering locally RSV through a 
biodegradable drug delivery system might be a potential treatment tool 
[2] to improve its bioavailability: intestinal metabolism. Resveratrol un-
dergoes various which includes changes oxidation, reduction immediately 
after ingestion [39]. In order to be efficient, RSV must act in a way in 
which to maximize its therapeutic effects and to lower its side effects. 
Therefore providing an efficient delivery system with no degradation or 
inactivation is of fundamental importance. On the other hand it must 
show no reaction with internal organism. We strongly believe that both 
of these are readily achievable by using our proposed system due to 
DNDs properties [40]. Over the last years, various systems, including 
gelatin, liposomes, ceramic, and micelles, have been developed for medi-
cal use [41]. Different results have shown that the oral bioavailability of 
resveratrol is almost zero. Obviously, one can think that the high concen-
tration of taken RSV has no importance like the case of in vitro experi-
ments [42]. In addition, isomerization from the trans to the cis form in 
solution (it is highly photosensitive compound susceptible to UV-induced 
isomerization, and rapid clearance from the circulation, makes it difficult 
to maintain bio efficacious concentrations of resveratrol in the blood and 
target tissues of humans [43][44]. Since resveratrol has poor water solu-
bility, it has to find other systems to provide distribution and bioavailabil-
ity [4] e.g. by binding to serum proteins [45]. In this article, we discuss 
the challenges in the delivery of resveratrol, with a focus on the use of 
carriers and novel nano-encapsulation systems to enhance the stability of 
resveratrol and its efficient release and uptake under in vitro and in vivo 
conditions (Fig. 8). Many bioactive compounds including phenolic com-
pounds are unstable once they are isolated from their natural source and 
need to be protected from the environment and undesirable interactions 
with other components. A potential way to skip the problems encoun-
tered in the delivery of resveratrol is nano-encapsulation, which involve 
the packaging of components within a secondary material and delivering 
them in nanometer scale. It also involves the stabilization of unstable 
bioactive compounds, protects them against undesirable interactions 
with the environment, masks astringency tastes, increase their bioavaila-
bility and potentially targets and controls the release of the bioactive 
compound at a desired target tissue in the body. To the best of our 
knowledge, in the literature are found more micro-encapsulation than 
nano. They are based on the use of surfactants, lipids, biopolymers, or 
mixtures of these components. The designed delivery systems include 
simple or mixed micelles stabilized by surfactants, single bioactive cores 
in shell particles (e.g., emulsion droplet) or in a polymeric matrix (e.g., 
hydrogel and coacervates), soluble bioactive–biopolymer complexes, or 
the more sophisticated multiple-core and structured multilayer systems 
[5]. 
 
Perspectives. Formulation of resveratrol with DNDs could improve the 
pharmaceutical properties of it, by providing high surface loading, im-
proved aqueous dispersibility, sustained tunable release, and enhanced 
retention in chemoresistant cells. These properties come from the rich-
ness of surface with hydrophilic groups (intrinsic hydrophilic surface), 
large surface-to-volume ratio, clusters formation, and biocompatibility of 
the DNDs. Our article proposes a new delivery system for resveratrol, to 
stabilize it against trans–cis isomerization, improve chemical stability 
(tendency to suffer oxidation and extreme photosensitivity), skip rapid 
metabolism and elimination, control its release at target sites in the 
body, protect resveratrol from degradation and improve its bioavailabil-
ity. It is reported that even administration of DNDs itself inhibited the 
appearance and growth of the tumor in white rats. Moreover, DNDs have 
been used to increase the dispersibility of hydrophobic drugs in water 
[46]. What we propose is a conjugate system between DND and one of 
the stilbenes, in our case the representative is to be resveratrol. It can 
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Figure 4. A schematic representation of some of the applications of nanodiamonds  
Figure 5. A schematic model representing the binding modes of DNDs 
with (A) Small molecules (B) Proteins and (C) DNA. 
 Bioimaging 
Fluorescence 
 
Light scattering 
Detonation nanodiamonds Industrial  applications  Proteins 
 Delivery agent 
Macromolecules Nucleic acids 
Small molecules Chemotherapeutic drugs 
  Ovarian steroides   
 Natural Mycoestrogenes Supplementary Stilbenes 
Estrogen   Phytoestrogenes  Isoflavonoids 
 Man-made  Phenolic Flavonoids 
    Lignin 
Figure 6. A schematic representation explaining the origin of stilbenes.  
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Name  Formula & Structure  Name  Formula & Structure  
cis-stilbene C14H12  trans-stilbene C14H12  
cis-resveratrol C14H12O3  trans-resveratrol C14H12O3  
trans-stilbene oxide C14H12O  trans-pinosylvin C14H12O2  
trans-4-stilbene-carbox-
aldehyde 
C15H12O  alpha-cyclohexyl-stilbene C20H22  
trans-4- stilbene-methanol C15H14O  4,4'-dimethylstilbene C16H16  
trans- piceatannol C14H12O4  trans-alpha methylstilbene C15H14  
trans-4- methoxy stilbene C15H14O  trans -4,4' diphenylstibene C26H20  
rhapontigenin 2,4-dinitro-2'- fluorostilbene C14H9FN2O4  C15H16O4  
HH
H
H
OH
OHHO
O
H
H
CHO
H
H
CH2OH
H
H
OH
OH
OH
OH
CH CH OCH3
OH
HO
OH
OCH3
CH CH NO2
NO2
F
CH3
CH3
H
CH3
CH3 CH3
C CH
OH
OH
HO
HO
OH
Table 3.  The most important compounds of stilbene family. 
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readily achieved due to the structure and surface functionality of DND 
making them ideal carriers for various drugs. We will make theoretical 
considerations on the ways of how resveratrol can be bound with DNDs. 
Basically there exist two modes: chemical bonding and physical adsorp-
tion procedures. 
 
Chemical bonding. The presence of various functional groups on the 
surface of DND particles enables several ways of purposeful surface mod-
ification which affects a considerable part of atoms constituting a DND 
particle since about 15% of atoms in a 4-nm particle are those located on 
its surface and are therefore accessible for modification [14]. Modifica-
tion can be performed both in a solvent and in the gas phase. Three ways 
of surface modification  seem  to  be  promising: oxida tion, reduction, 
and direct replacement of functional groups on the surface of DND clus-
ters, which follow different mechanisms. A fairly well studied modifica-
tion method is replacement of surface functional groups. Among a varie-
ty of surface functional groups, a considerable area is occupied by hy-
droxy groups that are convenient structural fragments for modification. It 
covalently adds to DND particles through the hydroxyl groups according 
to the Scheme 1. We believe that the coupling of RSV with chlorinated 
DNDs can be obtained through one of the hydroxy groups. The rate of 
this reaction depends on the concentration of RSV, steric hindrance and 
the acidity of specific hydroxyl group. The titration of trans(E) form with 
base has shown three significant steps corresponding to the mono-, di-, 
and tri- deprotonation of the system characterized by pKa values of 9.3, 
10.0, and 10.6. These values are according to the range of common phe-
nol acidity. The first deprotonation step is related to OH-4’ because the 
charge of the corresponding  phenolate ion can be delocalized over the 
whole molecule [47]. In the above scheme we propose the most favora-
ble situation of coupling between them, where the conformation of the 
molecule is less attacked and the effects of steric hindrance are low. 
Chemical attachment to DND surfaces affords greater robustness of the 
bio-molecular tag, since it is not based on electrostatic binding and also it 
can improve the hydrophobicity of both of them. On the other hand, the 
covalent surface modification of DNDs is a challenging task since the 
surface is covered with a variety of initial surface groups (from produc-
tion and purification treatment), and there is an inhomogeneity of the 
initial material. 
 
Physical adsorpition procedures. The properties of DNDs that make 
them ideal for biomedical applications is its large specific surface area 
(300 to 400 m2/g) and high adsorption capacities to proteins, enzymes, 
and other biological molecules, the ability to protect and deliver the 
therapeutic effects of the attached entities to the target site.  The release 
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Figure 7. Three-dimensional view of Resveratrol. a) Trans-RSV and b) Cis-RSV. Red balls represent oxygen atoms, purple balls represent carbon atoms 
and green balls represent hydrogen atoms. 
Figure 8. Different ways of RSV delivery. 
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of the molecule is also important for novel applications, but the mecha-
nism is to be studied. This simple process of loading cargo onto the carri-
er via physical interactions where the individuality of RSV is preserved, 
skips chemical reactions, which apart from being costly, can change the 
therapeutic activity of the attached entity by causing structural altera-
tions. The binding strength depends strongly on the surface termination 
of the considered diamond material. Surfaces with hydrogen dangling 
bonds are much less likely to absorb proteins due to the lack of polar 
interactions [17]. Therefore, they do not show non-specific adsorption of 
bioactive molecules. On the other hand, oxidized diamond surfaces are 
prone to these interactions [20]. So oxygen terminated DNDs can be 
anchored to molecules able to participate in hydrogen bonding, which 
presents our case of resveratrol, too. What we suspect is that binding 
affinity of resveratrol comes from both van-der-Waals interactions and 
hydrogen bonding (H-bonds) at (100) surface of DND. Conjugation based 
on this way, without employing chemical cross-linking, eliminates sys-
tematic effects, which are otherwise likely to occur due to uncontrollable 
drug diffusion. Thus, we are most confident that this novel approach will 
be the basis for new powerful strategies on RSV delivery. 
 
Conclusions. Although it is too early to admit for the efficiency of our 
proposed method, we believe that it is one of the most promise ways for 
drugs delivery. Further studies are needed to determine whether these 
predictions could be confirmed by experimental results. 
 
Abbreviations. DND stands for detonation nanodiamonds. RSV stands for 
resveratrol. 
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Scheme 1. Representation of coupling between DND and RSV. 
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